Research ExplorerPublicationsA prospective non-interventional study on the impact of tran...

A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation

Standard

A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation. / Cremers, Eline M P; de Witte, Theo; de Wreede, Liesbeth; Eikema, Diderik-Jan; Koster, Linda; van Biezen, Anja; Finke, Jürgen; Socié, Gerard; Beelen, Dietrich; Maertens, Johan; Nagler, Arnon; Kobbe, Guido; Ziagkos, Dimitris; Itälä-Remes, Maija; Gedde-Dahl, Tobias; Sierra, Jorge; Niederwieser, Dietger; Ljungman, Per; Beguin, Yves; Ozkurt, Zubeyde Nur; Anagnostopoulos, Achilles; Jindra, Pavel; Robin, Marie; Kröger, Nicolaus.

In: LEUKEMIA LYMPHOMA, Vol. 60, No. 10, 10.2019, p. 2404-2414.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Cremers, EMP, de Witte, T, de Wreede, L, Eikema, D-J, Koster, L, van Biezen, A, Finke, J, Socié, G, Beelen, D, Maertens, J, Nagler, A, Kobbe, G, Ziagkos, D, Itälä-Remes, M, Gedde-Dahl, T, Sierra, J, Niederwieser, D, Ljungman, P, Beguin, Y, Ozkurt, ZN, Anagnostopoulos, A, Jindra, P, Robin, M & Kröger, N 2019, 'A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation', LEUKEMIA LYMPHOMA, vol. 60, no. 10, pp. 2404-2414. https://doi.org/10.1080/10428194.2019.1594215

APA

Cremers, E. M. P., de Witte, T., de Wreede, L., Eikema, D-J., Koster, L., van Biezen, A., Finke, J., Socié, G., Beelen, D., Maertens, J., Nagler, A., Kobbe, G., Ziagkos, D., Itälä-Remes, M., Gedde-Dahl, T., Sierra, J., Niederwieser, D., Ljungman, P., Beguin, Y., ... Kröger, N. (2019). A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation. LEUKEMIA LYMPHOMA, 60(10), 2404-2414. https://doi.org/10.1080/10428194.2019.1594215

Vancouver

Cremers EMP, de Witte T, de Wreede L, Eikema D-J, Koster L, van Biezen A et al. A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation. LEUKEMIA LYMPHOMA. 2019 Oct;60(10):2404-2414. https://doi.org/10.1080/10428194.2019.1594215

Bibtex

@article{f1a2db9a6da74277bc9594031908ab34,
title = "A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation",
abstract = "Most myelodysplastic syndromes (MDS)-patients receive multiple red blood cell transfusions (RBCT). Transfusions may cause iron-related toxicity and mortality, influencing outcome after allogeneic HSCT. This prospective non-interventional study evaluated 222 MDS and CMML patients undergoing HSCT. Overall survival (OS), relapse-free survival (RFS), non-relapse mortality (NRM), and relapse incidence (RI) at 36 months were 52%, 44%, 25%, and 31%, respectively. Age, percentage of marrow blasts and severe comorbidities impacted OS. RFS was significantly associated with RBCT burden prior to HSCT (HR: 1.7; p = .02). High ferritin levels had a significant negative impact on OS and RI, but no impact on NRM. Administration of iron chelation therapy prior to HSCT did not influence the outcome, but early iron reduction after HSCT (started before 6 months) improved RFS significantly after transplantation (56% in the control group vs. 90% in the treated group, respectively; p = .04). This study illustrates the impact of RBCT and related parameters on HSCT-outcome. Patients with an expected prolonged survival after transplantation may benefit from early iron reduction therapy after transplantation.",
author = "Cremers, {Eline M P} and {de Witte}, Theo and {de Wreede}, Liesbeth and Diderik-Jan Eikema and Linda Koster and {van Biezen}, Anja and J{\"u}rgen Finke and Gerard Soci{\'e} and Dietrich Beelen and Johan Maertens and Arnon Nagler and Guido Kobbe and Dimitris Ziagkos and Maija It{\"a}l{\"a}-Remes and Tobias Gedde-Dahl and Jorge Sierra and Dietger Niederwieser and Per Ljungman and Yves Beguin and Ozkurt, {Zubeyde Nur} and Achilles Anagnostopoulos and Pavel Jindra and Marie Robin and Nicolaus Kr{\"o}ger",
year = "2019",
month = oct,
doi = "10.1080/10428194.2019.1594215",
language = "English",
volume = "60",
pages = "2404--2414",
journal = "LEUKEMIA LYMPHOMA",
issn = "1042-8194",
publisher = "informa healthcare",
number = "10",

}

RIS

TY - JOUR

T1 - A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation

AU - Cremers, Eline M P

AU - de Witte, Theo

AU - de Wreede, Liesbeth

AU - Eikema, Diderik-Jan

AU - Koster, Linda

AU - van Biezen, Anja

AU - Finke, Jürgen

AU - Socié, Gerard

AU - Beelen, Dietrich

AU - Maertens, Johan

AU - Nagler, Arnon

AU - Kobbe, Guido

AU - Ziagkos, Dimitris

AU - Itälä-Remes, Maija

AU - Gedde-Dahl, Tobias

AU - Sierra, Jorge

AU - Niederwieser, Dietger

AU - Ljungman, Per

AU - Beguin, Yves

AU - Ozkurt, Zubeyde Nur

AU - Anagnostopoulos, Achilles

AU - Jindra, Pavel

AU - Robin, Marie

AU - Kröger, Nicolaus

PY - 2019/10

Y1 - 2019/10

N2 - Most myelodysplastic syndromes (MDS)-patients receive multiple red blood cell transfusions (RBCT). Transfusions may cause iron-related toxicity and mortality, influencing outcome after allogeneic HSCT. This prospective non-interventional study evaluated 222 MDS and CMML patients undergoing HSCT. Overall survival (OS), relapse-free survival (RFS), non-relapse mortality (NRM), and relapse incidence (RI) at 36 months were 52%, 44%, 25%, and 31%, respectively. Age, percentage of marrow blasts and severe comorbidities impacted OS. RFS was significantly associated with RBCT burden prior to HSCT (HR: 1.7; p = .02). High ferritin levels had a significant negative impact on OS and RI, but no impact on NRM. Administration of iron chelation therapy prior to HSCT did not influence the outcome, but early iron reduction after HSCT (started before 6 months) improved RFS significantly after transplantation (56% in the control group vs. 90% in the treated group, respectively; p = .04). This study illustrates the impact of RBCT and related parameters on HSCT-outcome. Patients with an expected prolonged survival after transplantation may benefit from early iron reduction therapy after transplantation.

AB - Most myelodysplastic syndromes (MDS)-patients receive multiple red blood cell transfusions (RBCT). Transfusions may cause iron-related toxicity and mortality, influencing outcome after allogeneic HSCT. This prospective non-interventional study evaluated 222 MDS and CMML patients undergoing HSCT. Overall survival (OS), relapse-free survival (RFS), non-relapse mortality (NRM), and relapse incidence (RI) at 36 months were 52%, 44%, 25%, and 31%, respectively. Age, percentage of marrow blasts and severe comorbidities impacted OS. RFS was significantly associated with RBCT burden prior to HSCT (HR: 1.7; p = .02). High ferritin levels had a significant negative impact on OS and RI, but no impact on NRM. Administration of iron chelation therapy prior to HSCT did not influence the outcome, but early iron reduction after HSCT (started before 6 months) improved RFS significantly after transplantation (56% in the control group vs. 90% in the treated group, respectively; p = .04). This study illustrates the impact of RBCT and related parameters on HSCT-outcome. Patients with an expected prolonged survival after transplantation may benefit from early iron reduction therapy after transplantation.

U2 - 10.1080/10428194.2019.1594215

DO - 10.1080/10428194.2019.1594215

M3 - SCORING: Journal article

C2 - 30997844

VL - 60

SP - 2404

EP - 2414

JO - LEUKEMIA LYMPHOMA

JF - LEUKEMIA LYMPHOMA

SN - 1042-8194

IS - 10

ER -